Search Results - Isikwei, Emasenyie

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712

    Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712 by Tarlock, Katherine, Liu, Xiaowei, Minard, Charles G, Isikwei, Emasenyie A, Reid, Joel M, Horton, Terzah M, Fox, Elizabeth, Weigel, Brenda J, Cooper, Todd

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

    FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer by Duke, Elizabeth S, Barone, Amy K, Chatterjee, Somak, Mishra-Kalyani, Pallavi S, Shen, Yuan-Li, Isikwei, Emasenyie, Zhao, Hong, Bi, Youwei, Liu, Jiang, Rahman, Nam Atiqur, Wearne, Emily, Leighton, John K, Stephenson, Maritsa, Ojofeitimi, Idara, Scepura, Barbara, Nair, Abhilasha, Pazdur, Richard, Beaver, Julia A, Singh, Harpreet

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

    A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 by Davis, Kara L, Fox, Elizabeth, Isikwei, Emasenyie, Reid, Joel M, Liu, Xiaowei, Minard, Charles G, Voss, Stephan, Berg, Stacey L, Weigel, Brenda J, Mackall, Crystal L

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)

    Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615) by Foster, Jennifer H., Reid, Joel M., Minard, Charles, Woodfield, Sarah, Denic, Kristina Z., Isikwei, Emasenyie, Voss, Stephan D., Nelson, Marvin, Liu, Xiaowei, Berg, Stacey L., Fox, Elizabeth, Weigel, Brenda J.

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  5. 5
    A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors

    A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including ce... by Pilbeam, Kristy L., Pradhan, Kamnesh, Croop, James, Minard, Charles G., Liu, Xiaowei, Voss, Stephan D., Isikwei, Emasenyie, Berg, Stacey L., Reid, Joel M., Fox, Elizabeth, Weigel, Brenda J.

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  6. 6
    Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies

    Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies by McNulty, Caitlin M., Isikwei, Emasenyie A., Shrestha, Pragya, Snyder, Melissa R., Kabat, Brian F., Rabe, Kari G., Slager, Susan L., Parikh, Sameer A., Joshi, Avni Y.

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: